Answer
The terminal half-life of golimumab in healthy subjects is estimated to be approximately 12 ± 3 days.
Sources for this answer
- Simponi 50 mg solution for injection in pre filled syringeJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §5.2 Pharmacokinetic properties · Version 41Document updated
Sources checked